Case 1: Use of Niraparib in Ovarian Cancer
PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее
Clinical Use of Niraparib in Ovarian CancerПодробнее
Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее
Case 1: Diagnostic Tissue Testing in Ovarian CancerПодробнее
Niraparib Monotherapy in Late-Line Ovarian CancerПодробнее
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian CancerПодробнее
Niraparib Maintenance Therapy for Ovarian CancerПодробнее
Precision Medicine for Ovarian Cancer (2021)Подробнее
Case 1: Use of Maintenance Therapy in Ovarian CancerПодробнее
3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее
Personalized Dosing of Niraparib in Ovarian CancerПодробнее
Ovarian Cancer: Optimizing Treatment With NiraparibПодробнее
Management of Niraparib Dosing in Ovarian CancerПодробнее
Comment: Niraparib for ovarian cancerПодробнее
Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian CancerПодробнее
Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее
The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIAПодробнее
The AVANOVA study: niraparib and bevacizumab for ovarian cancerПодробнее
Case 1: Observation Versus Maintenance Therapy in Ovarian CancerПодробнее
Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian CancerПодробнее
Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian CancerПодробнее
Niraparib Shows Positive Data, Requires Different Dosing in Ovarian CancerПодробнее
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer TranscriptПодробнее